Shara Bledsoe
Family · Senatobia, MSNPI 1063776607
Payments from drug & device makers
Across 97 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$369
- AstraZeneca$289
- Lilly USA, LLC$239
- Johnson & Johnson$170
- Abbott$91
- Pfizer$90
- plus $484 from 14 others
What the payments were for
- Food & beverage$1,732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $369 |
| AstraZeneca | 12 | $289 |
| Lilly USA, LLC | 15 | $239 |
| Johnson & Johnson | 10 | $170 |
| Abbott | 4 | $91 |
| Pfizer | 5 | $90 |
| Boehringer Ingelheim | 5 | $88 |
| AbbVie | 3 | $51 |
| Merck | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| GSK | 2 | $28 |
| Boston Scientific | 1 | $25 |
| Bayer | 1 | $25 |
| Genentech USA, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Exact Sciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,732 in reported general payments places this provider in the 75th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 43 | $48,754 |
| OzempicSemaglutide | 23 | $26,910 |
| JardianceEmpagliflozin | 16 | $25,595 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $17,718 |
| FarxigaDapagliflozin Propanediol | 11 | $13,710 |
| XareltoRivaroxaban | 12 | $7,105 |
| Atorvastatin Calcium | 96 | $842 |
| Gabapentin | 56 | $833 |
| Rosuvastatin Calcium | 58 | $810 |
| Omeprazole | 56 | $614 |
| Levothyroxine Sodium | 62 | $563 |
| Ezetimibe | 24 | $543 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $538 |
| Potassium Chloride | 23 | $444 |
| Pantoprazole Sodium | 48 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $239 | $48,75443 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $88 | $43,31327 claims |
| Novo NordiskOzempic | $369 | $26,91023 claims |
| AstraZenecaFarxiga | $289 | $13,71011 claims |
| Johnson & JohnsonXarelto | $170 | $7,10512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,007 family providers in Mississippi.
Other family in Senatobia
- Kenneth HawkinsSenatobia$13K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.